Clinical trials: IPF and PPF
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
- Conditions
- Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Trial name
- UPWARD (NCT07722507)
- Testing
- Antifibrotic therapy
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
IPF and PPF
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
- Trial name
- NCT07192939
- Testing
- HRS-9813 capsules, HRS-9813 capsule mimetic
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pulmonary Fibrosis
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for…
- Trial name
- NCT07441408
- Testing
- BMS-986278
- Where
- 275 sites in United States, Argentina and 25 more
- Volunteers
- 2,380 people
- Sponsor
- Bristol-Myers Squibb
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen…
- Trial name
- PRIME-PPF (NCT06855329)
- Where
- 24 sites in United States, Australia and 11 more
- Volunteers
- 500 people
- Sponsor
- University of Massachusetts, Worcester
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study
This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact…
- Trial name
- NCT07743996
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.
- Trial name
- PALM-PPF (NCT07805785)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Volunteers
- 800 people
- Sponsor
- Insmed Incorporated
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
- Trial name
- AF-BMC (NCT07332117)
- Testing
- No Interventions, No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or…
- Trial name
- FIBRONEER™-ON (NCT06238622)
- Testing
- Nerandomilast
- Where
- 374 sites in United States, Argentina and 42 more
- Volunteers
- 1,666 people
- Sponsor
- Boehringer Ingelheim
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their…
- Trial name
- NCT07269262
- Testing
- SUPPORT-T Educational Intervention
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Medical University of South Carolina
Fibrotic Interstitial Lung Disease, IPF and PPF
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data…
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Trial name
- RESPOND-ILD (NCT07673237)
- Testing
- Spirometer, Oximeter, Scale
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
- Trial name
- NCT05943535
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 165 sites in United States, Argentina and 13 more
- Volunteers
- 698 people
- Sponsor
- United Therapeutics